Format

Send to

Choose Destination
Gynecol Oncol. 2015 Dec;139(3):541-5. doi: 10.1016/j.ygyno.2015.10.003. Epub 2015 Oct 9.

Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

Author information

1
Indiana University School of Medicine, Indianapolis, IN 46202, United States. Electronic address: lmhess@iupui.edu.
2
NRG Oncology/Gynecologic Oncology Group Statistics and Data Center, Buffalo, NY, United States. Electronic address: hhuang@gogstats.org.
3
University of Pennsylvania, Philadelphia, PA, United States. Electronic address: al_hanlon@comcast.net.
4
Tulane University, New Orleans, LA, United States. Electronic address: wrobinso@tulane.edu.
5
Kansas University Medical Center, Kansas City, KS, United States. Electronic address: rjohnson7@kumc.edu.
6
University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: schambers@uacc.arizona.edu.
7
The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: Robert-mannel@ouhsc.edu.
8
Greenville CCOP, Greenville, NC, United States. Electronic address: lpuls@ghs.org.
9
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, CO, United States. Electronic address: susan.davidson@ucdenver.edu.
10
Northern Indiana CCOP, Mishawaka, IN, United States. Electronic address: mmethod@mhopc.com.
11
Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: Shashi.lele@roswellpark.org.
12
Duke University Medical Center, Durham, NC, United States. Electronic address: havri001@mc.duke.edu.
13
The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: tina-nelson@ouhsc.edu.
14
University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: dalberts@uacc.arizona.edu.

Abstract

OBJECTIVES:

Changes in cognitive function have been identified in and reported by many cancer survivors. These changes have the potential to impact patient quality of life and functional ability. This prospective longitudinal study was designed to quantify the incidence of change in cognitive function in newly diagnosed ovarian cancer patients throughout and following primary chemotherapy.

METHODS:

Eligible patients had newly diagnosed, untreated ovarian cancer and had planned to receive chemotherapy. Web-based and patient reported cognitive assessments and quality of life questionnaires were conducted prior to chemotherapy, prior to cycle four, after cycle six, and six months after completion of primary therapy.

RESULTS:

Two-hundred-thirty-one evaluable patients entered this study between May 2010 and October 2011. At the cycle 4 time point, 25.2% (55/218) of patients exhibited cognitive impairment in at least one domain. At the post-cycle 6 and 6-month follow up time points, 21.1% (44/208) and 17.8% (30/169) of patients, respectively, demonstrated impairment in at least one domain of cognitive function. There were statistically significant, but clinically small, improvements in processing speed (p<0.001) and attention (p<0.001) but not in motor response time (p=0.066), from baseline through the six-month follow up time period.

CONCLUSIONS:

This was a large, prospective study designed to measure cognitive function in ovarian cancer. A subset of patients had evidence of cognitive decline from baseline during chemotherapy treatment in this study as measured by the web-based assessment; however, changes were generally limited to no more than one domain.

KEYWORDS:

Chemotherapy; Cognitive function; Ovarian cancer; Prospective trial; Quality of life

PMID:
26456812
PMCID:
PMC4698796
DOI:
10.1016/j.ygyno.2015.10.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center